Literature DB >> 29469245

Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.

Taeho Greg Rhee1,2,3, Somaia Mohamed4,5,6, Robert A Rosenheck4,5,6.   

Abstract

OBJECTIVE: A recent moderately long-term study found an antipsychotic to be more effective than an antidepressant as the next-step treatment of unresponsive major depressive disorder (MDD). It is thus timely to examine recent trends in the pharmacoepidemiology of antipsychotic treatment of MDD.
METHODS: Data from the 2006-2015 National Ambulatory Medical Care Survey, nationally representative samples of office-based outpatient visits in adults with MDD (ICD-9-CM codes 296.20-296.26 and 296.30-296.36) (n = 4,044 unweighted), were used to estimate rates of antipsychotic prescribing over these 10 years. Multivariable logistic regression analysis identified demographic and clinical factors independently associated with antipsychotic use in MDD.
RESULTS: Antipsychotic prescribing for MDD increased from 18.5% in 2006-2007 to 24.9% in 2008-2009 and then declined to 18.9% in 2014-2015. Visits with adults 75 years or older showed the greatest decline from 27.0% in 2006-2007 to 10.7% in 2014-2015 (OR for overall trend = 0.73; 95% CI, 0.56-0.95). The most commonly prescribed antipsychotic agents were aripiprazole, olanzapine, quetiapine, and risperidone. Antipsychotic prescription was associated with being black or Hispanic, having Medicare among adults under 65 years or Medicaid as a primary source of payment, and receiving mental health counseling, 3 or more concomitant medications, and diagnosis of cannabis use disorder (P < .01).
CONCLUSIONS: Antipsychotics, prescribed for about one-fifth of adults with MDD, increased and then declined from 2006 to 2015, reflecting, first, FDA approval and then concern about adverse effects in the elderly. Future research should track evolving trends following the publication of evidence of greater long-term effectiveness of antipsychotic than antidepressant next-step therapy in adults with MDD. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29469245      PMCID: PMC5932223          DOI: 10.4088/JCP.17m11970

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

2.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

3.  The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.

Authors:  Somaia Mohamed; Gary R Johnson; Julia E Vertrees; Peter D Guarino; Kimberly Weingart; Ilanit Tal Young; Jean Yoon; Theresa C Gleason; Katherine A Kirkwood; Amy M Kilbourne; Martha Gerrity; Stephen Marder; Kousick Biswas; Paul Hicks; Lori L Davis; Peijun Chen; AlexandraMary Kelada; Grant D Huang; David D Lawrence; Mary LeGwin; Sidney Zisook
Journal:  Psychiatry Res       Date:  2015-08-06       Impact factor: 3.222

Review 4.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

5.  Potentially Inappropriate Antidepressant Prescriptions Among Older Adults in Office-Based Outpatient Settings: National Trends from 2002 to 2012.

Authors:  Taeho Greg Rhee; Jon C Schommer; Benjamin D Capistrant; Ronald L Hadsall; Donald L Uden
Journal:  Adm Policy Ment Health       Date:  2018-03

6.  Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: An instrumental variable analysis.

Authors:  Taeho Greg Rhee; Benjamin D Capistrant; Jon C Schommer; Ronald S Hadsall; Donald L Uden
Journal:  Prev Med       Date:  2017-04-14       Impact factor: 4.018

7.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 8.  Definition and epidemiology of treatment-resistant depression.

Authors:  M Fava; K G Davidson
Journal:  Psychiatr Clin North Am       Date:  1996-06

Review 9.  Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder.

Authors:  Ashwin A Patkar; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

10.  Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.

Authors:  Somaia Mohamed; Douglas L Leslie; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

View more
  8 in total

1.  Coprescribing of Benzodiazepines and Opioids in Older Adults: Rates, Correlates, and National Trends.

Authors:  Taeho Greg Rhee
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-11-13       Impact factor: 6.053

2.  Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Addiction       Date:  2019-07-25       Impact factor: 6.526

3.  Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders.

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  J Affect Disord       Date:  2019-04-08       Impact factor: 4.839

4.  Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study.

Authors:  Jess G Fiedorowicz; Lisa Brown; James Li; Sagar V Parikh; Boadie W Dunlop; Brent P Forester; Richard C Shelton; Michael E Thase; Matthew Macaluso; Kunbo Yu; John F Greden
Journal:  Psychopharmacol Bull       Date:  2021-11-03

5.  Small Molecule Antipsychotic Aripiprazole Potentiates Ozone-Induced Inflammation in Airway Epithelium.

Authors:  Adam M Speen; Jessica R Hoffman; Hye-Young H Kim; Yael N Escobar; Grace E Nipp; Meghan E Rebuli; Ned A Porter; Ilona Jaspers
Journal:  Chem Res Toxicol       Date:  2019-09-11       Impact factor: 3.739

6.  Initiation of new psychotropic prescriptions without a psychiatric diagnosis among US adults: Rates, correlates, and national trends from 2006 to 2015.

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Health Serv Res       Date:  2018-10-17       Impact factor: 3.402

7.  Psychotropic and Opioid-Based Medication Use among Economically Disadvantaged African-American Older Adults.

Authors:  Mohsen Bazargan; Sharon Cobb; Cheryl Wisseh; Shervin Assari
Journal:  Pharmacy (Basel)       Date:  2020-04-27

8.  Effects of the 2009 USPSTF Depression Screening Recommendation on Diagnosing and Treating Mental Health Conditions in Older Adults: A Difference-in-Differences Analysis.

Authors:  Taeho Greg Rhee; Benjamin D Capistrant; Jon C Schommer; Ronald S Hadsall; Donald L Uden
Journal:  J Manag Care Spec Pharm       Date:  2018-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.